IDEAYA Biosciences, Inc.
IDYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | -0.37 | 6.18 | -5.74 |
| FCF Yield | -11.98% | -5.75% | -12.03% | -7.01% |
| EV / EBITDA | -6.22 | -14.51 | -11.39 | -15.38 |
| Quality | ||||
| ROIC | -30.31% | -21.54% | -16.22% | -14.14% |
| Gross Margin | 100.00% | 82.86% | 95.87% | 93.83% |
| Cash Conversion Ratio | 0.90 | 1.02 | 1.49 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -48.39% | -5.76% | 37.63% | – |
| Free Cash Flow Growth | -113.82% | -29.77% | -55.11% | -206.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 1.18 | 1.08 | 1.79 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.25 | -0.01 |
| Cash Conversion Cycle | 0.16 | -600.58 | -2,186.92 | -26,094.83 |